> top > docs > PubMed:10674443 > annotations

PubMed:10674443 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 9-13 UBERON:0003062 denotes node
T4 24-48 D002285 denotes ductal carcinoma in situ
T5 24-48 D002285 denotes ductal carcinoma in situ
T11 80-90 UBERON:0000029 denotes lymph node
T13 92-95 PR:Q9CQD6 denotes SLN
T14 92-95 PR:Q6SLE7 denotes SLN
T15 92-95 PR:000015247 denotes SLN
T17 92-95 PR:O00631 denotes SLN
T16 92-95 CVCL_S948 denotes SLN
T18 168-173 UBERON:0002391 denotes lymph
T19 183-189 UBERON:0000310 denotes breast
T20 183-196 D001943 denotes breast cancer
T21 183-196 D001943 denotes breast cancer
T22 211-214 PR:Q9CQD6 denotes SLN
T23 211-214 PR:Q6SLE7 denotes SLN
T24 211-214 PR:000015247 denotes SLN
T26 211-214 PR:O00631 denotes SLN
T25 211-214 CVCL_S948 denotes SLN
T27 228-232 UBERON:0003062 denotes node
T28 283-288 D009369 denotes tumor
T29 283-288 D009369 denotes tumor
T30 320-327 D004194 denotes disease
T31 320-327 D004194 denotes disease
T32 362-373 D006416 denotes hematoxylin
T33 362-373 CHEBI:51686 denotes hematoxylin
T34 362-373 CHEBI:5601 denotes hematoxylin
T35 362-373 D006416 denotes hematoxylin
T36 378-383 1310593 denotes eosin
T37 378-383 D004801 denotes eosin
T38 378-383 D004801 denotes eosin
T39 390-396 D004396 denotes stains
T40 390-396 D004396 denotes stains
T41 448-451 PR:Q9CQD6 denotes SLN
T42 448-451 PR:Q6SLE7 denotes SLN
T43 448-451 PR:000015247 denotes SLN
T45 448-451 PR:O00631 denotes SLN
T44 448-451 CVCL_S948 denotes SLN
T46 507-510 PR:Q9CQD6 denotes SLN
T47 507-510 PR:Q6SLE7 denotes SLN
T48 507-510 PR:000015247 denotes SLN
T50 507-510 PR:O00631 denotes SLN
T49 507-510 CVCL_S948 denotes SLN
T51 547-558 D007633 denotes cytokeratin
T54 631-637 CVCL_E025 denotes Cancer
T52 631-637 D009369 denotes Cancer
T53 631-637 D009369 denotes Cancer
T55 638-644 CVCL_E031 denotes Center
T56 679-683 PR:Q8FYW3 denotes pure
T57 679-683 PR:Q54QE4 denotes pure
T58 679-683 PR:P52558 denotes pure
T59 679-683 PR:P0AG18 denotes pure
T61 679-683 PR:000023640 denotes pure
T60 679-683 GO:0034023 denotes pure
T64 684-708 D002285 denotes ductal carcinoma in situ
T65 684-708 D002285 denotes ductal carcinoma in situ
T71 710-714 CVCL_5552 denotes DCIS
T70 710-714 D002285 denotes DCIS
T72 710-714 D002285 denotes DCIS
T73 771-774 PR:Q9CQD6 denotes SLN
T74 771-774 PR:Q6SLE7 denotes SLN
T75 771-774 PR:000015247 denotes SLN
T77 771-774 PR:O00631 denotes SLN
T76 771-774 CVCL_S948 denotes SLN
T78 817-824 D004194 denotes disease
T79 817-824 D004194 denotes disease
T80 849-855 UBERON:0000310 denotes breast
T82 910-914 CVCL_5552 denotes DCIS
T81 910-914 D002285 denotes DCIS
T83 910-914 D002285 denotes DCIS
T84 952-957 D009369 denotes tumor
T85 952-957 D009369 denotes tumor
T86 973-979 D004396 denotes stains
T87 973-979 D004396 denotes stains
T88 1059-1062 PR:Q7ZU29 denotes dye
T90 1059-1062 PR:P0A9Q1 denotes dye
T91 1059-1062 PR:000022123 denotes dye
T89 1059-1062 CHEBI:37958 denotes dye
T92 1067-1077 D013667 denotes technetium
T93 1067-1077 D013667 denotes technetium
T94 1067-1077 CHEBI:33353 denotes technetium
T95 1086-1092 CHEBI:17909 denotes sulfur
T96 1086-1092 D013455 denotes sulfur
T98 1086-1092 CHEBI:26833 denotes sulfur
T99 1086-1092 D013455 denotes sulfur
T97 1086-1092 10223 denotes sulfur
T100 1093-1100 D003102 denotes colloid
T101 1093-1100 D003102 denotes colloid
T102 1201-1207 D004396 denotes stains
T103 1201-1207 D004396 denotes stains
T105 1410-1414 CVCL_5552 denotes DCIS
T104 1410-1414 D002285 denotes DCIS
T106 1410-1414 D002285 denotes DCIS
T107 1415-1421 UBERON:0000310 denotes breast
T108 1415-1428 D001943 denotes breast cancer
T109 1415-1428 D001943 denotes breast cancer
T111 1454-1458 CVCL_5552 denotes DCIS
T110 1454-1458 D002285 denotes DCIS
T112 1454-1458 D002285 denotes DCIS
T113 1630-1637 D004194 denotes disease
T114 1630-1637 D004194 denotes disease
T116 1655-1659 CVCL_5552 denotes DCIS
T115 1655-1659 D002285 denotes DCIS
T117 1655-1659 D002285 denotes DCIS
T119 1702-1706 CVCL_5552 denotes DCIS
T118 1702-1706 D002285 denotes DCIS
T120 1702-1706 D002285 denotes DCIS
T121 1744-1751 D004194 denotes disease
T122 1744-1751 D004194 denotes disease
T123 1759-1762 PR:Q9CQD6 denotes SLN
T124 1759-1762 PR:Q6SLE7 denotes SLN
T125 1759-1762 PR:000015247 denotes SLN
T127 1759-1762 PR:O00631 denotes SLN
T126 1759-1762 CVCL_S948 denotes SLN
T128 1784-1803 UBERON:0001097 denotes axillary lymph node
T132 1874-1881 D004194 denotes disease
T133 1874-1881 D004194 denotes disease
T134 1913-1917 UBERON:0003062 denotes node
T135 1947-1956 D002277 denotes carcinoma
T136 1947-1956 D002277 denotes carcinoma
T138 1977-1981 CVCL_5552 denotes DCIS
T137 1977-1981 D002285 denotes DCIS
T139 1977-1981 D002285 denotes DCIS
T141 2073-2077 CVCL_5552 denotes DCIS
T140 2073-2077 D002285 denotes DCIS
T142 2073-2077 D002285 denotes DCIS
T143 2138-2144 UBERON:0000310 denotes breast
T144 2138-2151 D001943 denotes breast cancer
T145 2138-2151 D001943 denotes breast cancer
T147 2166-2170 CVCL_5552 denotes DCIS
T146 2166-2170 D002285 denotes DCIS
T148 2166-2170 D002285 denotes DCIS
T149 2286-2293 D004194 denotes disease
T150 2286-2293 D004194 denotes disease
T151 2465-2472 D004194 denotes disease
T152 2465-2472 D004194 denotes disease
T153 2541-2546 UBERON:0002391 denotes lymph
T155 2660-2664 CVCL_5552 denotes DCIS
T154 2660-2664 D002285 denotes DCIS
T156 2660-2664 D002285 denotes DCIS
T157 2697-2703 D004396 denotes stains
T158 2697-2703 D004396 denotes stains
T160 2725-2735 UBERON:0000029 denotes lymph node
T162 2736-2746 D009362 denotes metastases
T163 2736-2746 D009362 denotes metastases
T164 2825-2844 UBERON:0001097 denotes axillary lymph node
T169 2892-2896 CVCL_5552 denotes DCIS
T168 2892-2896 D002285 denotes DCIS
T170 2892-2896 D002285 denotes DCIS
T171 2918-2933 D061206 denotes micrometastases
T172 2918-2933 D061206 denotes micrometastases

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 183-196 HP_0003002 denotes breast cancer
T2 183-196 HP_0100013 denotes breast cancer
T3 190-196 HP_0002664 denotes cancer
T4 283-288 HP_0002664 denotes tumor

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-58 DRI_Background denotes Sentinel node biopsy in ductal carcinoma in situ patients.
T2 71-206 DRI_Outcome denotes Sentinel lymph node (SLN) mapping is an effective and accurate method of evaluating the regional lymph nodes in breast cancer patients.
T3 207-289 DRI_Outcome denotes The SLN is the first node that receives lymphatic drainage from the primary tumor.
T4 290-610 DRI_Unspecified denotes Patients with micrometastatic disease, previously undetected by routine hematoxylin and eosin (H&E) stains, are now being detected with the new technology of SLN biopsy, followed by a more detailed examination of the SLN that includes serial sectioning and cytokeratin immunohistochemical (CK IHC) staining of the nodes.
T5 620-775 DRI_Background denotes At Moffitt Cancer Center, 87 patients with newly diagnosed pure ductal carcinoma in situ (DCIS) lesions were evaluated by using CK IHC staining of the SLN.
T6 776-909 DRI_Approach denotes Patients with any focus of microinvasive disease, detected on diagnostic breast biopsy by routine H&E, were excluded from this study.
T7 910-1101 DRI_Background denotes DCIS patients, with biopsy-proven in situ tumor by routine H&E stains, underwent intraoperative lymphatic mapping, using a combination of vital blue dye and technetium-labeled sulfur colloid.
T8 1102-1215 DRI_Background denotes The excised SLNs were examined grossly, by imprint cytology, by standard H&E histology, and by IHC stains for CK.
T9 1216-1352 DRI_Outcome denotes All SLNs that had only CK-positive cells were subsequently confirmed malignant by a more detailed histological examination of the nodes.
T10 1362-1438 DRI_Approach denotes CK IHC staining was performed on 177 SLNs in 87 DCIS breast cancer patients.
T11 1439-1491 DRI_Background denotes Five of the 87 DCIS patients (6%) had positive SLNs.
T12 1492-1576 DRI_Approach denotes Three of these patients were only CK positive and two were both H&E and CK positive.
T13 1577-1688 DRI_Approach denotes Therefore, routine H&E staining missed microinvasive disease in three of five DCIS patients with positive SLNs.
T14 1689-1882 DRI_Outcome denotes In addition, DCIS patients with occult micrometastatic disease to the SLN underwent a complete axillary lymph node dissection, and the SLNs were the only nodes found to have metastatic disease.
T15 1883-2078 DRI_Outcome denotes Of interest, four of the five node-positive patients had comedo carcinoma associated with the DCIS lesion, and one patient had a large 9.5-cm low grade cribriform and micropapillary type of DCIS.
T16 2092-2326 DRI_Challenge denotes This study confirms that lymphatic mapping in breast cancer patients with DCIS lesions is a technically feasible and a highly accurate method of staging patients with undetected micrometastatic disease to the regional lymphatic basin.
T17 2327-2486 DRI_Outcome denotes This procedure can be performed with minimal morbidity, because only one or two SLNs, which are at highest risk for containing metastatic disease, are removed.
T18 2487-2632 DRI_Outcome denotes This allows the pathologist to examine the one or two lymph nodes with greater detail by using serial sectioning and CK IHC staining of the SLNs.
T19 2633-2882 DRI_Approach denotes Because most patients with DCIS lesions detected by routine H&E stains do not have regional lymph node metastases, these patients can safely avoid the complications associated with a complete axillary lymph node dissection and systemic chemotherapy.
T20 2883-3041 DRI_Background denotes However, DCIS patients with occult micrometastases of the regional lymphatic basin can be staged with higher accuracy and treated in a more selective fashion.